GCC-2
GCC-2 is a glycolipid. GCC-2 binds to CD1d and presents it to cells. GCC-2 induces Th1-biased cellular activation and IFN-γ production. GCC-2 inhibits antitumor activity in colon cancer tumor models and induces antigen-specific humoral immune responses. GCC-2 can be used for research on colon adenocarcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C54H97NO10
- Masse moléculaire:920.35
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
CD1d |
In Vitro
GCC-2 (1-1000 nM; 72 h) selectively promotes Th1-skewed immune responses through a CD1d-dependent mechanism in mouse splenocytes, with GCC-2 exhibiting a 17.8-fold higher maximal activity than αGalCer[1].
GCC-2 (100 nM; 2-24 h) is more efficiently presented and persists longer on the surface of DC2.4 cells than αGalCer[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Mouse splenocytes
-
Concentration:1-1000 nM
-
Incubation Time:72 h
-
Result:Exhibited maximal activities 17.8-fold higher than αGalCer.
Maintained Th1-biased cytokine profiles across the 1 to 1000 nM concentration range.
Induced higher IFN-γ levels and stronger Th1 polarization than branched analogs 16 and 17.
Pretreatment with an anti-CD1d monoclonal antibody significantly suppressed cytokine secretion.
-
Cell Line:DC2.4 cells
-
Concentration:100 nM
-
Incubation Time:2, 6, 12, 18, or 24 h
-
Result:Exhibited markedly enhanced L363 signals at 12, 18, and 24 h compared with αGalCer.
Showed the strongest L363 signals in DC2.4 cells after 18 h of treatment.
In Vivo
GCC-2 (i.p.) more effectively activates innate immune responses in mice, enhances coordinated NKT and NK cell activation, and promotes Th1-biased responses in vivo[1].
GCC-2 (1 nmol; i.v.; on days 3 and 10) induces a strong Th1-type cytokine response and potent antitumor activity in mice, and GCC-2 reduces the mean tumor volume to approximately 500 mm3 by day 30[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice (strain not specified)[1]
-
Dosage:2.33 nmol
-
Administration:i.p.
-
Result:Increased IFN-γ secretion by ∼12-fold relative to αGalCer and 28-fold relative to its linear analog 3.
-
Animal Model:BALB/c mice[1]
-
Dosage:1 nmol
-
Administration:i.v.; on days 3 and 10
-
Result:Reduced average tumor volume to approximately 500 mm3 on day 30.
Significantly prolonged survival relative to αGalCer.
Significantly increased IFN-γ production relative to αGalCer.
Chemical Information
-
Masse moléculaire 920.35
-
Formule C54H97NO10
-
SMILES
OC[C@H]([C@@H]([C@@H]([C@H]1O)O)O)O[C@@H]1OC[C@H](NC(CCC2=CC=CC(OCC3CCCCCCCCCCCCCCCCCC3)=C2)=O)[C@H](O)[C@@H](CCCCCCCCCCCCCCC)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GCC-2 Related Classifications
HY-189459 Related Classifications
Powered by Bioz